Log In
Print this Print this

KAN0439834 (formerly ROR-1 inhibitor)

  Manage Alerts
Collapse Summary General Information
Company Kancera AB
DescriptionROR1 inhibitor
Molecular Target Receptor tyrosine kinase-like orphan receptor 1 (ROR1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today